{"id":"NCT01483560","sponsor":"University of Glasgow","briefTitle":"REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)","officialTitle":"Phase 3 Study of Metformin in Adults With Type 1 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2017-03-19","completion":"2017-04-18","firstPosted":"2011-12-01","resultsPosted":"2019-06-03","lastUpdate":"2019-06-19"},"enrollment":493,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Metformin","otherNames":["Glucophage"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Metformin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.","primaryOutcome":{"measure":"Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)","timeFrame":"0, 12 months, 24 months, 36 months","effectByArm":[{"arm":"Metformin","deltaMin":0.773,"sd":0.14},{"arm":"Placebo","deltaMin":0.791,"sd":0.183}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":14},"locations":{"siteCount":24,"countries":["Australia","Canada","Denmark","Netherlands","United Kingdom"]},"refs":{"pmids":["38837240","28615149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":219},"commonTop":["Gastrointestinal","Opthalmic adverse events","Hypersensitivity to Metformin","Cardiovascular","Neurological"]}}